Cortland Advisers Cut Chevron (CVX) Position By $3.88 Million; Last Week Oramed Pharmaceuticals Inc. (ORMP) Analysts

January 14, 2018 - By Linda Rogers

Among 4 analysts covering Oramed Pharmaceuticals (NASDAQ:ORMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oramed Pharmaceuticals had 9 analyst reports since August 14, 2015 according to SRatingsIntel. The stock of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has “Buy” rating given on Monday, December 11 by B. Riley & Co. The firm has “Buy” rating given on Friday, October 2 by Rodman & Renshaw. Zacks upgraded Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) on Friday, August 14 to “Sell” rating. FBR Capital initiated the shares of ORMP in report on Thursday, November 19 with “Outperform” rating. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 22. On Thursday, October 1 the stock rating was initiated by H.C. Wainwright with “Buy”. As per Thursday, October 5, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) rating on Tuesday, December 1. H.C. Wainwright has “Buy” rating and $25 target. See Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) latest ratings:

11/12/2017 Broker: B. Riley & Co Rating: Buy New Target: $20 Maintain
11/12/2017 Broker: FBR Capital Rating: Buy New Target: $20.0
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $25.0 Maintain
05/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $25.0 Maintain

Cortland Advisers Llc decreased Chevron Corp (CVX) stake by 2.72% reported in 2017Q3 SEC filing. Cortland Advisers Llc sold 33,191 shares as Chevron Corp (CVX)’s stock declined 3.45%. The Cortland Advisers Llc holds 1.19 million shares with $139.56 million value, down from 1.22M last quarter. Chevron Corp now has $253.76 billion valuation. The stock increased 0.78% or $1.03 during the last trading session, reaching $133.6. About 7.23M shares traded or 34.97% up from the average. Chevron Corporation (NYSE:CVX) has risen 6.68% since January 14, 2017 and is uptrending. It has underperformed by 10.02% the S&P500.

Investors sentiment decreased to 2 in 2017 Q3. Its down 4.00, from 6 in 2017Q2. It is negative, as 2 investors sold Oramed Pharmaceuticals Inc. shares while 2 reduced holdings. 2 funds opened positions while 6 raised stakes. 255,973 shares or 20.44% less from 321,734 shares in 2017Q2 were reported. 14,725 were reported by Wells Fargo & Co Mn. Plante Moran Financial Advisors Ltd Liability Corporation has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Jpmorgan Chase And reported 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Glenmede Na owns 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 20,000 shares. 500 were reported by Royal Bankshares Of Canada. Bancorp Of America De reported 0% stake. Savings Bank Of Montreal Can has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). 14,766 were accumulated by Morgan Stanley. Susquehanna Intl Grp Incorporated Llp holds 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 18,762 shares. Barclays Plc holds 41,186 shares or 0% of its portfolio. Tower Rech Cap Limited Liability Com (Trc) invested in 0% or 393 shares. One Trading L P has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Jfs Wealth Ltd Llc reported 500 shares. Pnc Fin Gru owns 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 21,200 shares. Deutsche Bankshares Ag invested in 0% or 29,434 shares.

The stock decreased 1.25% or $0.11 during the last trading session, reaching $8.7. About 18,246 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has risen 2.79% since January 14, 2017 and is uptrending. It has underperformed by 13.91% the S&P500.

Since August 2, 2017, it had 0 buys, and 1 insider sale for $761,906 activity. Shares for $761,906 were sold by Kidron Miriam on Wednesday, August 2.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $124.46 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

Analysts await Chevron Corporation (NYSE:CVX) to report earnings on January, 26. They expect $1.19 earnings per share, up 440.91% or $0.97 from last year’s $0.22 per share. CVX’s profit will be $2.26 billion for 28.07 P/E if the $1.19 EPS becomes a reality. After $1.03 actual earnings per share reported by Chevron Corporation for the previous quarter, Wall Street now forecasts 15.53% EPS growth.

Among 34 analysts covering Chevron Corporation (NYSE:CVX), 22 have Buy rating, 1 Sell and 11 Hold. Therefore 65% are positive. Chevron Corporation had 100 analyst reports since August 4, 2015 according to SRatingsIntel. UBS maintained the shares of CVX in report on Monday, May 2 with “Neutral” rating. The firm earned “Hold” rating on Wednesday, October 18 by Societe Generale. The firm earned “Buy” rating on Monday, October 30 by Citigroup. On Tuesday, November 7 the stock rating was maintained by RBC Capital Markets with “Sell”. The company was maintained on Friday, March 24 by RBC Capital Markets. Citigroup maintained the stock with “Buy” rating in Friday, July 21 report. The stock has “Underperform” rating by Macquarie Research on Wednesday, September 23. The firm has “Buy” rating by Jefferies given on Tuesday, October 3. Nomura initiated it with “Neutral” rating and $85 target in Friday, March 18 report. The company was downgraded on Tuesday, January 10 by HSBC.

Investors sentiment decreased to 0.95 in 2017 Q3. Its down 0.08, from 1.03 in 2017Q2. It worsened, as 43 investors sold CVX shares while 696 reduced holdings. 121 funds opened positions while 584 raised stakes. 1.18 billion shares or 1.43% more from 1.16 billion shares in 2017Q2 were reported. Covington Inv Advsrs Incorporated has 2.46% invested in Chevron Corporation (NYSE:CVX). Rhumbline Advisers owns 3.35 million shares for 0.86% of their portfolio. Yorktown Mngmt And Rech Company invested in 12,550 shares. Hodges Capital has invested 0.1% in Chevron Corporation (NYSE:CVX). Iconiq Cap Limited Liability Corp reported 2,400 shares. Eads And Heald Counsel invested in 17,264 shares or 1.26% of the stock. Virginia Retirement Sys Et Al holds 1.14% of its portfolio in Chevron Corporation (NYSE:CVX) for 799,232 shares. Bancorpsouth Incorporated holds 0.22% or 19,150 shares. Farmers And Merchants Invests, Nebraska-based fund reported 73,635 shares. Perigon Wealth Ltd invested 1.42% in Chevron Corporation (NYSE:CVX). Wasatch accumulated 64,859 shares or 0.1% of the stock. Longer Investments Incorporated accumulated 22,980 shares or 2.41% of the stock. Institute For Wealth Mgmt Ltd Liability Com holds 0.56% of its portfolio in Chevron Corporation (NYSE:CVX) for 14,480 shares. Ig Invest Ltd has 827,128 shares for 0.5% of their portfolio. Synovus Financial reported 0.44% of its portfolio in Chevron Corporation (NYSE:CVX).

Since August 1, 2017, it had 0 buys, and 4 insider sales for $11.07 million activity. Deily Linnet F sold $248,274 worth of Chevron Corporation (NYSE:CVX) on Wednesday, August 16. $3.06 million worth of Chevron Corporation (NYSE:CVX) was sold by Pate R. Hewitt. 31,000 Chevron Corporation (NYSE:CVX) shares with value of $3.43M were sold by JOHNSON JAMES WILLIAM. Shares for $4.33M were sold by Yarrington Patricia E.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>